Loading organizations...

§ Private Profile · Louisville, KY, USA
Talaris Therapeutics is a technology company.
Talaris Therapeutics develops therapies aimed at transforming the standard of care in solid organ transplantation and severe immune and blood disorders. The company's core approach focuses on durable immune tolerance, particularly in kidney transplant recipients, to reduce or eliminate the need for lifelong immunosuppression. This involves a cell therapy platform designed to induce a new, fully functional immune system in patients, thereby preventing rejection without chronic drug dependency.
The company was founded on the insight that current transplantation practices, while life-saving, necessitate continuous immunosuppression with significant side effects. This led to a commitment to develop a novel cell therapy approach that leverages the body's own immune system to achieve tolerance. While specific founder details are no longer publicly accessible through current channels, their pioneering work laid the groundwork for addressing a critical unmet medical need in transplantation.
Talaris's product targets patients undergoing solid organ transplants and those suffering from severe immune and blood disorders who could benefit from immune system resetting. The company's vision centers on establishing a new paradigm in patient care, moving beyond mere organ survival to provide recipients with a significantly improved quality of life free from the burdens of chronic immunosuppressive regimens. The long-term goal is to make durable immune tolerance a widely accessible reality for these patient populations.
Talaris Therapeutics has raised $365.0M across 3 funding rounds.
Talaris Therapeutics has raised $365.0M in total across 3 funding rounds.
Talaris Therapeutics has raised $365.0M across 3 funding rounds. Most recently, it raised $150.0M Other Equity in May 2021.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| May 7, 2021 | $150M Venture Round | — | — | Announced |
| Oct 6, 2020 | $115M Series B | Surveyor Capital, Viking Global Investors | Aisling Capital, BlackRock, Blackstone, Cormorant Asset Management, Eventide Asset Management, Invus, Logos Capital, Longitude Capital, Pamoja Capital, Qiming Venture Partners USA | Announced |
| Apr 1, 2019 | $100M Series A | Scott Requadt | Qiming Venture Partners USA, Sandip Agarwala | Announced |
Talaris Therapeutics is a clinical‑stage cell‑therapy company developing allogeneic, tolerance‑inducing cellular treatments aimed at reducing or eliminating chronic immunosuppression for organ transplant recipients and inducing durable remission in severe autoimmune and immune‑mediated blood disorders[4]. Talaris’s lead program, FCR001 (also described as an allogeneic cell therapy to establish durable immune tolerance), advanced through Phase 2 studies and was the centerpiece of the company’s development and financing strategy[4][2].
High‑Level Overview
Origin Story
Core Differentiators
Role in the Broader Tech / Biotech Landscape
Quick Take & Future Outlook
Overall, Talaris built a scientifically rooted, potentially transformative cell‑therapy platform aimed at eliminating lifelong immunosuppression; its near‑term prospects hinge on demonstrating durable clinical benefit at scale and successfully navigating operational and strategic challenges highlighted during its recent restructuring and corporate review[4][3][5].
Talaris Therapeutics has raised $365.0M in total across 3 funding rounds.
Talaris Therapeutics's investors include Surveyor Capital, Viking Global Investors, Aisling Capital, BlackRock, Blackstone, Cormorant Asset Management, Eventide Asset Management, Invus, Logos Capital, Longitude Capital, Pamoja Capital, Qiming Venture Partners USA.